The FDA last week approved Jacobus Pharmaceuticals’ Ruzurgi for the treatment of Lambert-Eaton myasthenic syndrome (or LEMS), a rare neuromuscular disorder. Only one other drug is approved to treat LEMS, Catalyst Pharmaceuticals’ Firdapse, which currently holds preferred status for 7% of covered lives, and is not covered for 11% of lives. Firdapse made waves for its $375,000 list price when it was approved in December. Pricing information for Ruzurgi has not yet been released.

SOURCE: MMIT Analytics, as of 5/9/19